US 10946080
Compositions and methods for combination therapy with dengue virus and dendritic cells
granted A61KA61K2039/572A61K2039/585
Quick answer
US patent 10946080 (Compositions and methods for combination therapy with dengue virus and dendritic cells) held by PrimeVax Immuno-Oncology expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- PrimeVax Immuno-Oncology
- Grant date
- Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/572, A61K2039/585, A61K2239/31, A61K2239/57